US Broker Ratings

QuidelOrtho Corporation (QDEL) Investor Outlook: Analyzing a Potential 33.66% Upside in the Healthcare Sector

QuidelOrtho Corporation (NASDAQ: QDEL) is a prominent player in the healthcare sector, specializing in medical devices, particularly diagnostic testing solutions. With a market capitalization of $1.95 billion, this U.S.-based company..

Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring a 56.89% Upside Potential

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stands out in the biotechnology sector with a market capitalization of $2.78 billion. As a player in the healthcare industry, Apellis is focused on addressing..

Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: Unveiling a Potential 60.89% Upside with Innovative Endocrine Solutions

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), headquartered in San Diego, California, stands as a beacon in the biotechnology sector, focusing on novel therapeutics for rare endocrine diseases and related tumors. With..

Immunovant, Inc. (IMVT) Stock Analysis: Exploring a 51.55% Upside Potential in the Biotech Sector

Immunovant, Inc. (IMVT), a prominent player in the biotechnology sector, has captured the attention of investors with its clinical-stage developments targeting autoimmune diseases. The New York-based company focuses on innovative..

Scholar Rock Holding Corporation (SRRK) Stock Analysis: Biotechnology Innovator with 12% Upside Potential

Scholar Rock Holding Corporation (NASDAQ: SRRK) stands out in the biotechnology sector with its innovative approach to treating serious diseases through targeted protein growth factor therapies. The Massachusetts-based company has..

PROCEPT BioRobotics (PRCT): A Robotics Innovator with a 71% Potential Upside

For investors with a keen eye on the healthcare sector, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) presents an intriguing prospect. Specializing in medical devices, this San Jose-based company is at the..

Viking Therapeutics (VKTX): Analyst Ratings Indicate a Potential Upside of Over 194%

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, is garnering significant attention from investors with its promising drug pipeline and substantial potential upside. With a market capitalization of $3.59..

Arcellx, Inc. (ACLX) Stock Analysis: Unpacking a 63.90% Potential Upside in the Biotech Sector

Arcellx, Inc. (NASDAQ: ACLX), a promising player in the biotechnology sector, has caught the attention of investors with its robust pipeline of immunotherapies targeting cancer and other incurable diseases. As..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Potential Upside with Innovative Rare Disorder Treatments

PTC Therapeutics, Inc. (PTCT) stands out in the biotechnology sector with its focus on developing and commercializing treatments for rare disorders. Headquartered in Warren, New Jersey, PTC Therapeutics is making..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 37.5% Potential Upside in Biotech

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a prominent player in the biotechnology sector, presents a compelling case for investors seeking exposure to the high-growth healthcare industry. Specializing in rare neuroendocrine diseases,..

Oscar Health, Inc. (OSCR) Stock Analysis: Navigating Through a Volatile Market with a Strategic Outlook

Oscar Health, Inc. (NYSE: OSCR) is carving out a unique space in the healthcare sector, offering innovative health plans and technological platforms aimed at transforming the industry. With its current..

Nuvalent, Inc. (NUVL): Investor Outlook with a 33% Potential Upside

Nuvalent, Inc. (NASDAQ: NUVL) has emerged as a notable player in the biotechnology sector, focusing on innovative cancer therapies. As a clinical-stage biopharmaceutical company, Nuvalent is dedicated to developing targeted..

Cytokinetics, Incorporated (CYTK) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector

Cytokinetics, Incorporated (NASDAQ: CYTK), a prominent player in the biotechnology industry, has been catching the eye of investors with a compelling potential upside of 41.06%. This late-stage biopharmaceutical company is..

Sarepta Therapeutics (SRPT) Stock Analysis: Navigating a Challenging Biotech Landscape with a Potential Upside

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a prominent player in the biotechnology sector, primarily focusing on revolutionary treatments for rare diseases. Specializing in RNA-targeted therapeutics and gene therapies, the company..

Vaxcyte, Inc. (PCVX) Stock Analysis: Strong Analyst Consensus and Nearly 94% Upside Potential

Vaxcyte, Inc. (NASDAQ: PCVX), a promising player in the biotechnology sector, is capturing investor attention with its ambitious pipeline of innovative vaccines aimed at combating bacterial infectious diseases. With a..

Avidity Biosciences, Inc. (RNA) Stock Analysis: A Biotech Powerhouse with 434% Revenue Growth and Promising Clinical Trials

Avidity Biosciences, Inc. (NASDAQ: RNA) stands as a promising player in the biotechnology sector, captivating investor interest with its revolutionary approach to RNA therapeutics. Notably, the company has achieved an..

Merit Medical Systems, Inc. (MMSI) Stock Analysis: Exploring a 27% Upside Potential

Merit Medical Systems, Inc. (NASDAQ: MMSI) is a noteworthy player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $4.84 billion, the..

RadNet, Inc. (RDNT) Stock Analysis: A Healthcare Gem with a 25% Upside Potential

RadNet, Inc. (NASDAQ: RDNT), a leader in the healthcare diagnostics and research sector, offers a compelling opportunity for investors seeking growth in the medical imaging space. With a market capitalization..

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring the 3.39% Potential Upside in Biotech Innovation

For investors with an eye on the biotechnology sector, Akero Therapeutics, Inc. (NASDAQ: AKRO) stands out as a compelling prospect. With its focus on tackling serious metabolic diseases, Akero is..

Bruker Corporation (BRKR) Stock Analysis: Navigating a 7.43% Potential Upside Amidst Industry Challenges

Bruker Corporation (NASDAQ: BRKR), a prominent player in the healthcare sector specializing in medical devices, presents a fascinating investment opportunity. With a market capitalization of $7.65 billion, Bruker is a..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds